Open Orphan Plc (GB:HVO) has released an update.
hVIVO plc has announced a £2.5 million contract to establish the world’s first Omicron BA.5 challenge model using its new CL3 quarantine facilities in Canary Wharf. The study, which will recruit vaccinated 18-30 year-olds, aims to support the future testing of antivirals and vaccines by establishing a safe and measurable disease model. This groundbreaking work, scheduled to start in Q4 2024, will be pivotal for hVIVO’s expansion into new markets and the ongoing global effort against COVID-19.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.
